Collegium Pharmaceutical (NASDAQ:COLL) Now Covered by Analysts at Oppenheimer

Research analysts at Oppenheimer started coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report issued on Wednesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $50.00 price target on the specialty pharmaceutical company’s stock. Oppenheimer’s target price indicates a potential upside of 119.49% from the company’s current price.

A number of other equities analysts also recently commented on COLL. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Piper Sandler restated a “neutral” rating and issued a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Leerink Partners started coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target for the company. Finally, Needham & Company LLC lowered their price objective on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.71.

Collegium Pharmaceutical Trading Down 1.1%

NASDAQ:COLL opened at $22.78 on Wednesday. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The business’s 50 day moving average is $28.68 and its two-hundred day moving average is $32.45. Collegium Pharmaceutical has a 52 week low of $21.65 and a 52 week high of $50.79. The company has a market cap of $741.72 million, a PE ratio of 18.37 and a beta of 0.72.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.68 EPS. On average, analysts predict that Collegium Pharmaceutical will post 6.19 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Collegium Pharmaceutical during the second quarter valued at about $196,972,000. Jupiter Topco LLC bought a new position in Collegium Pharmaceutical in the 2nd quarter valued at about $77,743,000. Janus Henderson Group PLC increased its stake in Collegium Pharmaceutical by 26.0% during the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after buying an additional 377,073 shares during the period. Bank of America Corp DE acquired a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $9,882,000. Finally, Bank of New York Mellon Corp acquired a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $8,506,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.

Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain.